ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,199 MXN | -0.60% |
|
+7.61% | +63.89% |
| 11:00am | Musk wins pay approval but still faces Tesla's floundering stock and rich valuation | RE |
| 06-13 | Employer coverage for weight-loss drugs rises sharply, survey finds | RE |
| Sales 2024 * | 42.98B 801B 59.12B | Sales 2025 * | 52.62B 981B 72.38B | Capitalization | 795B 14,821B 1,094B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 222B 16.41B | Net income 2025 * | 16.55B 308B 22.77B | EV / Sales 2024 * | 18.9 x |
| Net Debt 2024 * | 18.07B 337B 24.85B | Net Debt 2025 * | 15B 279B 20.63B | EV / Sales 2025 * | 15.4 x |
| P/E ratio 2024 * |
66.1
x | P/E ratio 2025 * |
47.5
x | Employees | 43,000 |
| Yield 2024 * |
0.59% | Yield 2025 * |
0.68% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
| 1 day | -0.60% | ||
| 1 week | +7.61% | ||
| Current month | +16.91% | ||
| 1 month | +27.56% | ||
| 3 months | +28.26% | ||
| 6 months | +57.77% | ||
| Current year | +63.89% |
1 week
15 724.00
16 330.00
1 month
12 808.9216 330.00
Current year
9 980.0016 330.00
1 year
7 452.7516 330.00
3 years
4 427.0116 330.00
5 years
1 970.0016 330.00
10 years
743.6716 330.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Ruth Gimeno
PSD | President | - | - |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 16,199 | -0.60% | 123 |
| 24-06-12 | 16,297 | +1.72% | 92 |
| 24-06-11 | 16,022 | +1.62% | 191 |
| 24-06-10 | 15,767 | +0.36% | 1,170 |
| 24-06-07 | 15,710 | +4.36% | 1,581 |
End-of-day quote Mexican S.E., June 12, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
883.3
USD
Average target price
855.4
USD
Spread / Average Target
-3.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.20% | 350B | |
| +18.67% | 328B | |
| +7.48% | 294B | |
| +17.91% | 245B | |
| +1.23% | 222B | |
| +11.75% | 215B | |
| +3.64% | 160B | |
| -3.96% | 157B | |
| -2.35% | 118B |
- Stock Market
- Equities
- LLY Stock
- LLY * Stock
